anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Classifier generation methods are described in which features used in classification (e.g., mass spectral peaks) are selected, or deselected using bagged filtering. A development sample set is split into two subsets, one of which is used as a training set the other of which is set aside. We define a classifier (e.g., K-nearest neighbor, decision tree, margin-based classifier or other) using the training subset and at least one of the features (or subsets of two or more features in combination). We apply the classifier to a subset of samples. A filter is applied to the performance of the classifier on the sample subset and the at least one feature is added to a “filtered feature list” if the classifier performance passes the filter. We do this for many different realizations of the separation of the development sample set into two subsets, and, for each realization, different features or sets of features in combination. After all the iterations are performed the filtered feature list is used to either select features, or deselect features, for a final classifier.
The invention belongs to the technical field of traditional Chinese medicines, and provides a pyretolysis traditional Chinese medicine composition and a preparation method. Through the composition, body symptoms, with pyrexia as the main and heaviness in head and body, nasal obstruction and the like as the auxiliaries, caused by the upper respiratory infection and influenza are prevented and treated. The pyretolysis traditional Chinese medicine composition is prepared by scutellaria baicalensis, wild buckwheats, radix bupleuri, ginger processed pinellia, honeysuckles, fructus forsythiae, rhodiola rosea, the notopterygium root, ephedra, gypsum, fried bitter almonds, liquorice, folium isatidis, cordate houttuynia and male fern rhizome according to a certain proportion. The pyretolysis traditional Chinese medicine composition has the effects of clearing away heat and toxic materials, removing acute communicable diseases to repel foulness and ventilating the lung to arrest cough. The composition has the obvious curative effects on treating the symptoms of pyrexia, head and body pains, nasal obstruction and nose running, pharyngalgia and limb tiredness caused by the influenza and the upper respiratory infection. Compared with a product of the same class, when the composition is used for treating pyrexia caused by upper respiratory infection, effect taking is rapid, the antipyretic time is short, and the curative effect is obvious; and the preclinical experimental study and the clinical experimental study of the composition have been completed.
The invention provides isolated polynucleotide molecules, including plasmids;  viral vectors; and transfected host cells that comprise a DNA sequence encoding an infectious RNA sequence encoding a North American PRRS virus; and also North American PRRS viruses encoded thereby. The invention further provides isolated infectious RNA molecules encoding a North American PRRS virus. The invention also provides isolated polynucleotide molecules, infectious RNA molecules, viral vectors, and transfected host cells encoding genetically-modified North American PRRS viruses; and genetically-modified North American PRRS viruses encoded thereby. The invention also provides vaccines comprising such plasmids, RNA molecules, viral vectors, and North American PRRS viruses, and methods of using these vaccines in swine and in other animals. Also provided are isolated polynucleotide molecules, viral vectors, and transfected host cells that comprise a nucleotide sequence encoding a peptide of a North American PRRS virus. These viral vectors and transfected host cell lines are useful in providing peptides to compensate for mutated peptide coding sequences of DNA sequences encoding genetically-modified North American PRRS  viruses so that functional virions can be generated.
<P>PROBLEM TO BE SOLVED: To provide a method of easily manufacturing a supermolecule nano-assembly at room temperature without using a synthetic ligand and a template and a supermolecule nano-assembly.  <P>SOLUTION: This supermolecule nano-assembly is manufactured by the method having a step of mixing a transition metallic salt and nucleotide in water at room temperature. The transition metallic ions and nucleotide voluntarily form a supermolecule nano-assembly by self-organization. When a rare-earth salt is used as a transition metallic salt, a rare-earth nano-particle having strong fluorescent light emission and high magnetic moment can be provided. When a silver salt is used as a transition metallic salt, a nano-fiber is provided. When the concentration of a silver salt and nucleotide is increased, a hydrogel is generated.  <P>COPYRIGHT: (C)2008,JPO&INPIT
A process for injecting nanometer-scaled fibers directly into an intended body site of a patient. The process includes the steps of (a) preparing a precursor fluid to the fibers and (b) injecting the precursor fluid into the intended body site under the influence of an electrical field established between two electrodes to produce the nanometer-scaled fibers for forming a reinforcement preform. A polymer is then optionally injected into the intended body site to form a nano fiber-polymer composite structure. The composite structure may contain interconnected macro pores wherein cells can grow and proliferate. This composite scaffold is useful for tissue engineering. The injected nano fibers and composite structure may also be used as a means of controlled drug release or bone reinforcement.
The invention relates to an extract of a mixed crystal of diterpene lactone ingredients with anti-tumor activity such as Ergolide (Erg.) and Bigelovin (Big.), a preparation method thereof, an anti-tumor medicament using the extract as an active ingredient and application thereof to the anti-tumor medicament. Compared with the prior art, an extraction method of the invention improves extraction efficiency, reduces the times of recrystallization and greatly increases crystallization quantity. In addition, the Erg. is not separated from the Big., so the separation step is simplified, the activity of the Big. with better activity is retained, and resources are utilized completely.
Exercise training sessions will be performed 3 times per week for 12 weeks. The initial training sessions will include 6 sets of FES-rowing for 5 min at 60% of VO2 peak with a work-to-rest ratio of 2:1. Participants unable to row continuously for 5 min will row for 2-4 min with 30-second breaks incorporated until they achieve sets totaling 30 min. The goal is for each volunteer to achieve an exercise intensity of 70-85% maintained for a continuous 30-40 min performed 3 times each week.
Will receive a clopidogrel loading dose of 600 mg PO, then a daily dose of clopidogrel 75 mg PO until the angioplasty is performed. After coronary intervention, a daily dose of clopidogrel 150 mg PO for 7 days will be given, followed by a daily single dose of clopidogrel (75 mg PO) for 21 days. Maintenance therapy will be clopidogrel daily dose of 75 mg PO thereafter, until the end of the study.
The THRIVE study is a cluster randomized trial, using a community-based participatory research approach, of "healthy makeovers" in eight convenience stores owned and operated by the Chickasaw Nation and Choctaw Nation of Oklahoma. The study will test the ability of tribal nations to increase fruit and vegetable purchasing and consumption among tribal members through environmental and policy approaches. Investigators hypothesize that tribal members exposed to the highest doses of the intervention (i.e. those who visit the intervention convenience stores the most) will increase their fruit and vegetable intake. Individual-level changes in fruit and vegetable intake will be measured via a survey administered to a cohort of 1600 American Indian shoppers before and after the intervention. A multimedia manual, Website, and documentary film will be created as part of the implementation of THRIVE to engage tribal citizens, enhance local knowledge, and guide other tribes to improve their food and physical activity environments.
Cardiac Failure: Sympathetic stimulation is a vital component supporting circulatory function in congestive heart failure, and beta blockade carries the potential hazard of further depressing myocardial contractility and precipitating more severe failure. In hypertensive and angina patients who have congestive heart failure controlled by digitalis and diuretics, metoprolol should be administered cautiously.

In Patients Without a History of Cardiac Failure: Continued depression of the myocardium with beta-blocking agents over a period of time can, in some cases, lead to cardiac failure. At the first sign or symptom of impending cardiac failure, patients should be fully digitalized and/or given a diuretic. The response should be observed closely. If cardiac failure continues, despite adequate digitalization and diuretic therapy, metoprolol tartrate should be withdrawn.
Procedure for the ex-vivo study of the initial response of different cell types in atherosclerosis. The novelty of this model lies in the incubation of the cells of interest with the complete secretoma of the atheroma plaques to evaluate the cellular response. This incubation allows a more direct study of the cellular response to factors secreted by atheromatous plaques, instead of using isolated factors (vegf, sdf-1). This procedure would allow the evaluation of strategies to modulate the cellular response in response to atherosclerotic damage, for example in the case of endothelial progenitor cells (ecps), to promote vascular remodeling in therapies based on the use of these cells, although it can equally be applied to any cell type associated with atherosclerosis. It also allows to evaluate the effect of drugs in this initial framework of cellular response to atherosclerosis. (Machine-translation by Google Translate, not legally binding)
Acute-on-chronic liver failure (ACLF) is characterized by an acute hepatic insult happening in a patient with underlying cirrhosis with compromised hepatic reserve leading to development of systemic inflammation, sepsis, and organ failure resulting in poor outcome in majority. While Asia Pacific Association for Study of Liver Diseases (APASL) emphasizes on early diagnosis before development of organ failure, European Association for Study of Liver Diseases (EASL) mandates the presence of organ failures to define ACLF. There is a lack of consensus definition of pediatric ACLF although recent APASL guidelines have tried to address the issue. While Wilson disease (WD) and autoimmune hepatitis (AIH) are the most common cause of underlying cirrhosis in children, acute viral hepatitis and flares of WD and AIH are the commonest acute precipitating events. Poor outcomes [death and liver transplantation (LT)] ranging from 19 to 59% have been reported. Prognosis in pediatric ACLF is usually better than that in adults due to greater proportion of treatable etiologies, lesser organ failures, comorbidities and better hepatic reserves. APASL ACLF Research Consortium (AARC) score more than or equal to 11 is predictive of poor 28-90 d mortality. Treatment of pediatric ACLF relies mainly on prompt diagnosis and medical management of a potentially treatable etiology of underlying cirrhosis. Bridging therapies, especially high volume plasma exchange can be initiated early as a bridge to LT or native liver recovery. Those with no improvement in 4-7 d should undergo LT before development of sepsis or multi-organ failure.
FIELD: medicine, pharmacy. SUBSTANCE: neurotropic drug is a potentiated form of antibody-antiserum raised to brain-specific protein S-100. This form is prepared by successive multiple dilution and vertical shaking of solution antibody-antiserum in neutral solvent by homeopathic procedure. Drug stimulates regenerative process without adverse effects effectively. Invention can be used for correction of impaired immune homeostasis accompanying with alternations of psychosomatic functions and/or biological responses by many-sided effect on brain integrative activity. EFFECT: enhanced effectiveness of drug, absence of adverse effects. 9 ex
Active tDCS using tDCS device (Neuroelectrics Inc., Simi Valley, CA, USA) will deliver a small direct current through two sponge surface electrodes (5cm × 5cm, soaked with 15 mM NaCL). The anodal electrode will be placed over the M1 contralateral to the worst somatic pain area (C3, EEG 10/20 system) and the cathode over the supraorbital area contralateral to the anodal electrode. A constant current of 2 mA intensity will be applied for 20 minutes once a day for 5 consecutive days.
PURPOSE: A composition and a functional food containing Olibanum ethanol extract are provided to suppress pancreatic cancer cell growth and to effectively treat and prevent pancreatic cancer. CONSTITUTION: A composition for preventing and treating pancreatic cancer contains Olibanum ethanol extract as an active ingredient, extracted using 95% ethanol at 50 Deg. C. for 24 hours and drying and concentrating at 45 Deg. C. The composition also contains pharmaceutically acceptable carriers or diluents. A functional food for preventing pancreatic cancer contains the Olibanum ethanol extract as an active ingredient and sitologically acceptable food additives. [Reference numerals] (AA) Relative cell survival rate
A colloidal injectable iron preparation comprises the product produced by mixing a precaramelized sugar or sugar mixture, a solution or suspension of a ferric compound, and a suitable alkali to ensure that the pH value of the preparation is 7.5 or over.  The sugar may be sucrose, dextrose, fructose, mannose, arabinose, lactose, galactose, raffinose, rhamnose, sorbose, xylose or any mixture thereof, and the caramelization may be effected by heating the sugar from 180 DEG -205 DEG  C. at a reduced pressure of 1-60 mm. of mercury until it has lost between 10-15 per cent of its original dry weight.  Specified ferric compounds are (a) soluble ferric salts such as the chloride, nitrate, sulphate or acetate, and double salts such as ferric ammonium sulphate, (b) ferric oxy-salts preparable by dissolving ferric hydroxide in a solution of one of the above specified ferric salts, dialysed iron solution B.P.C. and freshly prepared and washed hydrated ferric oxide, and (c) any ferric compound capable of yielding ferric hydroxide when rendered alkaline in the presence of caramel, provided no chemically or therapeutically disadvantageous substance is simultaneously produced or introduced. Suitable alkalis are sodium, potassium, ammonium, lithium, magnesium and calcium hydroxides, sodium and potassium carbonates, sodium acetate and monoethanolamine.  Either the caramelised sugar or the final product may be dialysed against distilled water to make the final product iso-osmotic with human blood.  The preparation may be mixed with a water-miscible solvent such as methanol, ethanol or acetone to precipitate the colloid which may be separated and dissolved in distilled water.
Static neck muscle self-stretching exercises were performed for 30 min. after the TENS procedure. Every muscle in the neck region (head rotator cuff, neck stair muscles, upper part of the trapezius muscle, scapula levator muscle, semiscapular neck muscle, upper oblique head muscle, girdle head and neck muscles, and deep anterior neck flexor muscles) were stretched 3 times for 30 seconds per muscle group. While performing exercises, the subjects applied resistance with their hands. All exercises were performed without causing pain.
PURPOSE:To prepare the title copolymer contg. a lower amt. of tin and exhibiting high safety with a higher efficiency than that of the conventional method of preparation, by using a specified small amt. of stannous octanoate with lactide and glycolide and polymerizing them at a high temp. in a specified temp. range. CONSTITUTION:In a method for obtaining a dl-lactic acid-glycolic acid copolymer contg. 50-60mol.% dl-lactic acid unit and 40-50mol.% glycolic acid unit and whose logarithmic viscosity measured in chloroform is 0.4-0.6 from lactide and glycolide, the copolymn. is carried out by using 0.005-0.015wt.% stannous octanoate based on the amt. of the lactide and glycolide in the presence of a polymn. regulator (e.g., dl-lactic acid or glycolic acid) at 200-230 deg.C. It is thereby possible to prepare efficiently the title copolymer having said dl-lactic acid unit, glycolic acid unit and logarithmic viscosity whose tin content is 50ppm or less and being usable for a base material of a safe and sustained-release medicine.
In this operation, the surgeon will make a skin incision and carefully identify nerves that were likely to have been injured during the amputation surgery. The nerves are then "cleaned up" to enhance the possibility of healthy healing. Then the surgeon takes a small sample from a muscle (usually one close by to the nerves that are being operated on but sometimes through a second incision in the arm or leg, depending on the exact medical situation) and form something called a "muscle graft". The muscle graft is used to wrap the cleaned ends of the nerves mentioned above. This is thought to be helpful in directing the nerve healing process and reducing the risk of developing pain in the future. This operation takes 1 - 3 hours and occurs in the hospital. Follow up requires six to seven clinic visits with the surgeon over the course of one year, at which time standard questionnaires will be used to assess pain.
Two intravenous boluses of 2-3 mg/kg each of ketamine will be administered 5 minutes apart and immediately followed by a continuous infusion of 5-10 mcg/kg/min. Based on both clinical or electrographic responses, dosage will be increased every 10 minutes or longer, using 2 to 10 mcg/kg/ min increments, up to 60 mcg/kg/min. Maximum duration of infusion will be of 7 days.
Antibacterial prophylaxis is recommended in patients at high risk of infection, specifically patients undergoing acute leukemia induction therapy or hematopoietic stem cell transplant (HSCT) who are expected to have profound neutropenia (ANC\<100 neutrophils/milliliter) for more than seven days.

Xerava™ (eravacycline) is a synthetic halogenated tetracycline class antibiotic, with a broad spectrum of activity including many multi-drug resistant strains of bacteria. It is not an agent used for treatment of febrile neutropenia, making eravacycline a very attractive alternative to consider in this prophylactic setting. Adverse effects with this agent are minimal including infusion site reactions and gastrointestinal disorders. Eravacycline has activity against MRSA, VRE, and Clostridioides difﬁcile, all of which are common problems in this patient population. It also covers the majority of enteric gram-negative pathogens while also producing satisfactory tissue penetration and adequate plasma concentrations, which has classically been a concern with prior agents. Eravacycline has activity against coagulase-negative staphylococcus, which is a common catheter-related infection in leukemia and HSCT patients. The primary objective will be report the incidence of breakthrough infections during eravacycline prophylaxis for hematologic malignancy patients with prolonged neutropenia.
A method and system for predicting the resistance of a disease to a therapeutic agent is provided. Further provided is a method and system for designing a therapeutic treatment agent for a patient afflicted with a disease. Specifically, the methods use a trained neural network to interpret genotypic information obtained from the disease. The trained neural network is trained using a database of known or determined genotypic mutations that are correlated with phenotypic therapeutic agent resistance. The present invention also provides methods and systems for predicting the probability of a patient developing a genetic disease. A trained neural network for making such predictions is also provided. Also provided is a method and system for determining the genetic basis of therapeutic agent resistance.
DARTNA is a culturally-adaptable therapeutic drum behavior therapy that incorporates drumming, talking circles, and uses the 12 Steps of Alcoholics Anonymous (AA)/Narcotics Anonymous (NA) program within the conceptual framework of the Northern Plains Medicine Wheel. The Northern Plains Medicine Wheel is widely utilized as a conceptual framework and integrative approach to health and wellness for AI/ANs. This intervention consists of 12 sessions provided 2 times weekly over 6 weeks.
Pulmonary alveolar epithelial cell injury is considered the main pathological and physiological change in acute lung injury. Ferroptosis in alveolar epithelial cells is one of crucial factors contributing to acute lung injury (ALI). Therefore, reducing ferroptosis and repair epithelial barrier is very necessary. More and more evidence suggested that FGF10 plays an important role in lung development and repair after injury. However, the relationship between FGF10 and ferroptosis remains unclear. This study aims to explore the regulatory role of FGF10 on ferroptosis in ALI. Differential gene expression analysis indicated that genes associated with ferroptosis showed that FGF10 can significantly alleviate LPS induced lung injury and epithelial barrier damage by decreasing levels of malonaldehyde(MDA), and lipid ROS. SIRT1 activator (Resveratrol) and inhibitor (EX527) are used in vivo showed that FGF10 protects ferroptosis of pulmonary epithelial cells through SIRT1 signal. Furthermore, knockdown of FGFR2 gene reduced the protective effect of FGF10 on acute lung injury in mice and SIRT1 activation. After the application of NRF2 inhibitor ML385 in vitro, the results showed that SIRT1 regulated the expression of ferroptosis related proteins NRF2, GPX4 and FTH1 are related to activation of NRF2. These data indicate that SIRT-ferroptosis was one of the critical mechanisms contributing to LPS-induced ALI. FGF10 is promising as a therapeutic candidate against ALI through inhibiting ferroptosis.
OBJECTIVE: To determine if adding lumbar neuromuscular control retraining exercises to a 12-week program of strengthening exercises had greater effect for improving disability than 12 weeks of strengthening exercises alone in people with chronic low back pain (LBP). DESIGN: Single-center, participant- and assessor-blinded, comparative effectiveness randomized controlled trial. METHODS: Sixty-nine participants (31 females; 29 males; mean age: 46.5 years) with nonspecific chronic LBP were recruited for a 12-week program involving lumbar extension neuromuscular retraining in addition to resistance exercises (intervention) or 12 weeks of resistance exercises alone (control). The primary outcome measure was the Oswestry Disability Index. Secondary outcome measures included the Numeric Rating Scale, Tampa Scale for Kinesiophobia, Pain Self-Efficacy Questionnaire, and the International Physical Activity Questionnaire. Outcomes were measured at baseline, 6 weeks, and 12 weeks. RESULTS: Forty-three participants (22 control, 21 intervention) completed all outcome measures at 6 and 12 weeks. Fourteen participants were lost to follow-up, and 12 participants discontinued due to COVID-19 restrictions. Both groups demonstrated clinically important changes in disability, pain intensity, and kinesiophobia. The difference between groups with respect to disability was imprecise and not clinically meaningful (mean difference, -4.4; 95% CI: -10.2, 1.4) at 12 weeks. Differences in secondary outcomes at 6 or 12 weeks were also small with wide confidence intervals. CONCLUSIONS: Adding lumbar neuromuscular control retraining to a series of resistance exercises offered no additional benefit over resistance exercises alone over a 12-week period. J Orthop Sports Phys Ther 2024;54(5):1-10. Epub 18 March 2024. doi:10.2519/jospt.2024.12349.